How to buy Novo Nordisk stock | 19 Nov price $102.63

Novo Nordisk is a biotechnology business based in the US. Novo Nordisk shares (NVO.US) are listed on the NYSE and all prices are listed in US dollars. Its last market close was $115.74 – a decrease of 0.63% over the previous day. Novo Nordisk employs 69,260 staff and has a trailing 12-month revenue of around $258 billion.

How to buy shares in Novo Nordisk

Open a brokerage account. Choose from our top broker picks or compare brokers in depth. Then, complete an application.
Fund your account. Add money to your account via bank transfer, debit card or credit card.
Search the platform by ticker symbol. NVO in this case.
Choose an order type. Place a market order or limit order with your preferred number of shares or dollar amount.
Submit the order. It's that simple.

The whole process can take as little as 15 minutes. You'll need a smartphone or computer, an internet connection, your passport or driving licence and a means of payment.

Go to site

Easy to use app

100 free trades signup offer
Easy-to-use platform
Low fees
Student and young investor discounts

Go to site

Low margin rates

Access to international stock exchanges
Low margin rates
Powerful research tools

Go to site

CA & US trading

6% cash rebate plus $2,200 in trading perks
Low transaction fees
Easy-to-use app

Our selection of top picks is based on the same criteria as our annual Stock Trading Platform Awards. This is updated yearly to reflect changes in the market.

"Best for" picks are those we've evaluated to be best for specific product features or categories – you can read our full methodology here. If we show a "Promoted" pick, it's been chosen from among our commercial partners and is based on factors that include special features or offers, and the commission we receive.

This isn't an exhaustive list of all the trading platforms out there. What's best for you depends on your own investing strategy, budget and financial goals.

Is it a good time to buy Novo Nordisk stock?

Review technicals and fundamentals to help you determine if now's a good time for you to invest.

Technical analysis

View Novo Nordisk's price performance, share price volatility, historical data and technicals.

Use our graph to track the performance of NVO stock over time.

Historical closes compared with the last close of $115.74

1 week (2024-11-13)	-2.10%
1 month (2024-10-20)	-7.73%
3 months (2024-08-20)	-8.33%
6 months (2024-05-20)	-8.41%
1 year (2023-11-20)	20.10%
2 years (2022-11-20)	119.11%
3 years (2021-11-20)	126.56%
5 years (2019-11-20)	362.55%

The gauge below shows real-time ratings that are based on 26 popular indicators such as moving averages, for specific time periods. It's not a recommendation but is simply technical analysis that can form part of your research.

Finder might not agree with the analysis and we take no responsibility. We also give no representations or warranty on the accuracy or completeness of the information provided on this page.

Is Novo Nordisk under- or over-valued?

Valuing a stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of overall performance. However, analysts commonly use some key metrics to help gauge value. Check out the Novo Nordisk P/E ratio, PEG ratio and EBITDA.

Novo Nordisk's current stock price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 40x. In other words, Novo Nordisk's stocks trade at around 40x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the United States stock markets on average as of November 09, 2023 (20.44). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Novo Nordisk's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.7872. A PEG ratio over 1 can be interpreted as meaning shares are overvalued at the current rate of growth, or may anticipate an acceleration in growth.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Novo Nordisk's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $126.6 billion ($1 CAD).

The EBITDA is a measure of Novo Nordisk's overall financial performance and is widely used to measure a its profitability.

Frequently asked questions

Novo Nordisk's shares were split on a 2:1 basis on 19 September 2023. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Novo Nordisk shares which in turn could have impacted Novo Nordisk's share price.
It's as easy to sell Novo Nordisk as it is to buy! Here's how to sell Novo Nordisk stocks that you already own.
1. Open your investment app. If you've got one with desktop access, you can log in online
2. Go to your portfolio. This should be in the main menu
3. Find your shares. You may be able to search your portfolio
4. Choose how many you'd like to sell. You'll be able to review the price and see how much you'll receive
5. Sell your Novo Nordisk shares. Your investment platform will let you know when your shares are sold

Novo Nordisk financials

Revenue TTM	$270.6 billion
Operating margin TTM	47.43%
Gross profit TTM	$148.5 billion
Return on assets TTM	21.47%
Return on equity TTM	88.73%
Profit margin	35.01%
Book value	$27.07
Market capitalisation	$478.1 billion

TTM: trailing 12 months

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.